Monopar Therapeutics Inc. (MNPR) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $6.71K; Additional Paid in Capital, Common StockUSD $229.47M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $91.32K; Retained Earnings (Accumulated Deficit)USD $-98.72M.
- 2026-03-31: Common Stock, Value, IssuedUSD $6.70K; Additional Paid in Capital, Common StockUSD $228.69M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $98.52K; Retained Earnings (Accumulated Deficit)USD $-93.40M.
- 2025-12-31: Common Stock, Value, IssuedUSD $6.69K; Additional Paid in Capital, Common StockUSD $227.20M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $131.39K; Retained Earnings (Accumulated Deficit)USD $-89.51M.
- 2025-09-30: Common Stock, Value, IssuedUSD $6.66K; Additional Paid in Capital, Common StockUSD $225.85M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $11.70K; Retained Earnings (Accumulated Deficit)USD $-84.31M.
Monopar Therapeutics Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.71K | $229.47M | $91.32K | $-98.72M | $130.85M | (m) | 3 month · $1.43M | (m) | (m) | (m) |
| 2026-03-31 | $6.70K | $228.69M | $98.52K | $-93.40M | $135.39M | (m) | 3 month · $1.69M | (m) | (m) | (m) |
| 2025-12-31 | $6.69K | $227.20M | $131.39K | $-89.51M | $137.83M | (m) | 12 month · $4.84M | (m) | (m) | (m) |
| 2025-09-30 | $6.66K | $225.85M | $11.70K | $-84.31M | $141.56M | (m) | 3 month · $1.10M | (m) | (m) | (m) |
| 2025-06-30 | $6.13K | $132.99M | $77.58K | $-80.87M | $52.20M | (m) | 3 month · $1.28M | (m) | (m) | (m) |
| 2025-03-31 | $6.12K | $132.03M | $-21.78K | $-78.42M | $53.59M | (m) | 3 month · $1.36M | (m) | (m) | (m) |
| 2024-12-31 | $6.10K | $130.79M | $35.99K | $-75.79M | $55.04M | (m) | 12 month · $1.14M | (m) | (m) | (m) |
| 2024-09-30 | $3.52K | $69.82M | $-10.99K | $-64.87M | $4.95M | 3 month · $2.60K | 3 month · $199.12K | (m) | (m) | (m) |
| 2024-06-30 | $17.60K | $69.63M | $8.26K | $-63.56M | $6.09M | (m) | 3 month · $334.39K | (m) | (m) | (m) |
| 2024-03-31 | $17.48K | $69.30M | $4.23K | $-61.85M | $7.48M | 3 month · $81.93K | 3 month · $328.66K | (m) | (m) | (m) |
| 2023-12-31 | $2.98K | $65.81M | $-14.13K | $-60.21M | $5.59M | 12 month · $98.23K | 12 month · $1.90M | (m) | (m) | (m) |
| 2023-09-30 | $14.20K | $64.99M | $3.95K | $-58.39M | $6.61M | 3 month · $8.22K | 3 month · $474.14K | (m) | (m) | (m) |
| 2023-06-30 | $13.90K | $64.25M | $7.22K | $-56.44M | $7.84M | 3 month · $26.52K | 3 month · $473.30K | (m) | (m) | (m) |
| 2023-03-31 | $13.22K | (m) | $31.79K | $-54.24M | $8.94M | 3 month · $37.66K | 3 month · $476.21K | (m) | $63.14M | (m) |
| 2022-12-31 | $12.95K | $61.87M | $8.94K | $-51.80M | $10.09M | 12 month · $87.61K | 12 month · $1.64M | (m) | $61.87M | (m) |
| 2022-09-30 | $12.86K | (m) | $42.98K | $-48.91M | $12.51M | 3 month · $13.19K | 3 month · $390.74K | (m) | $61.36M | (m) |
| 2022-06-30 | $12.70K | (m) | $17.47K | $-46.51M | $14.52M | 3 month · $35.85K | 3 month · $357.29K | (m) | $60.99M | (m) |
| 2022-03-31 | $12.62K | (m) | $-3.74K | $-43.75M | $16.97M | (m) | 3 month · $499.81K | (m) | $60.70M | (m) |
| 2021-12-31 | $12.60K | (m) | $-3.16K | $-41.29M | $18.94M | (m) | (m) | (m) | $60.22M | (m) |
| 2021-09-30 | $12.59K | (m) | $-5.15K | $-38.61M | $21.28M | (m) | (m) | (m) | $59.88M | (m) |
| 2021-06-30 | $12.58K | (m) | $-5.16K | $-36.15M | $23.35M | (m) | (m) | (m) | $59.50M | (m) |
| 2021-03-31 | $12.57K | (m) | $-5.10K | $-34.07M | $25.10M | (m) | (m) | (m) | $59.16M | (m) |
| 2020-12-31 | $11.45K | (m) | $-7.87K | $-32.19M | $15.69M | (m) | (m) | (m) | $47.87M | 12 month · $-130.57K |
| 2020-09-30 | $11.45K | (m) | $-10.04K | $-30.06M | $17.49M | (m) | (m) | (m) | $47.55M | 3 month · $-7.14K |
| 2020-06-30 | $10.74K | (m) | $-11.55K | $-28.42M | $12.15M | (m) | (m) | (m) | $40.57M | 3 month · $-116.61K |
| 2020-03-31 | $10.62K | (m) | $-15.01K | $-26.97M | $12.40M | (m) | (m) | (m) | $39.37M | 3 month · $-2.16K |
| 2019-12-31 | $10.59K | (m) | $-10.97K | $-25.88M | $12.63M | (m) | (m) | (m) | $38.51M | (m) |
| 2019-09-30 | $9.29K | (m) | $-12.20K | $-24.67M | $4.62M | (m) | (m) | (m) | $29.30M | (m) |
| 2019-06-30 | $9.29K | (m) | $-23.94M | $-3.46K | $5.13M | (m) | (m) | (m) | $29.06M | (m) |
| 2019-03-31 | $9.29K | (m) | $-4.52K | $-23.03M | $5.77M | (m) | (m) | (m) | $28.80M | (m) |
| 2018-12-31 | $9.29K | (m) | $-2.40K | $-21.66M | $6.92M | (m) | (m) | (m) | $28.57M | (m) |
| 2018-09-30 | $9.29K | (m) | $-2.38K | $-20.77M | $7.58M | (m) | (m) | (m) | $28.33M | (m) |
| 2018-06-30 | $9.29K | (m) | $-1.58K | $-20.13M | $8.12M | (m) | (m) | (m) | $28.24M | (m) |
| 2018-03-31 | $9.29K | (m) | (m) | $-19.30M | $8.86M | (m) | (m) | (m) | $28.15M | (m) |
| 2017-12-31 | $9.29K | (m) | $0.00 | $-18.43M | $9.62M | (m) | (m) | $0.00 | $28.04M | (m) |
| 2016-12-31 | $0.00 | (m) | (m) | $-1.87M | $2.83M | (m) | (m) | $116.00 | $4.70M | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | $2.75M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |